Article citationsMore>>

Moucari, R., Mackiewicz, V., Lada, O., Ripault, M-P., Castelnau, C., Martinot-Peignoux, M., Dauvergne, A., Asselah, T., Boyer, N., Bedossa, P., Valla, D., Vidaud, M., Nicolas-Chanoine, M.-H. and Marcellin, P. (2009) Early Serum HBs Ag Drop: A Strong Predictor of Sustained Virological Response to Pegylated Interferon Alfa-2a in Hbe Ag-Negative Patients. Hepatology, 49, 1151-1157.
http://dx.doi.org/10.1002/hep.22744

has been cited by the following article:

• TITLE: Treatment of Chronic Viral Hepatitis with Pegylated Interferon in Ivory Coast

  AUTHORS: Henriette Ya Kissi Anzouan-Kacou, Aboubacar Demba Bangoura, Djenabou Diallo, Yacouba Adéhouni, Adjeka Stanislas Doffou, Hartrydt Dimitri Kouamé, Alassan Kouamé Mahassadi, Mamert Fulgence Yao Bathaix, Alain Koffi Attia, Aya Thérèse Ndri-Yoman

  KEYWORDS: HBV, HCV, Pegylated Interferon, Ribavirine, Africa

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.6 No.3, March 14, 2016

  ABSTRACT: Background: In the Ivory Coast, chronic infection by hepatitis B and C virus is the leading cause of cirrhosis and hepatocellular carcinoma. The absence of universal health coverage makes the treatment inaccessible to all. Objectives: To assess the efficacy of Pegylated Interferon in clinical practice in patients with chronic viral hepatitis B and C and determine the hematologic side effects. Patients and Methods: A descriptive retrospective study from January 2012 to November 2013 on a cohort of patients chronic carriers of hepatitis B virus (n = 11) treated with Pegylated Interferon to 180 mcg per week and hepatitis C virus (n = 30) treated with a combination therapy associating pegylated Interferon to 180 mcg per week and Ribavirin assayed according to the genotype. Results: Out of 1860 patients seen in hepatogastroenterology consultation 422 had viral hepatitis B or C that is a prevalence of 22.7% and 41 patients were treated (9.7%) by Pegylated Interferon. Among these 41 patients mentioned earlier, 30 had HCV (73.17%) with a case of HIV + HVC co-infection, 11 patients had HBV (26.83%) including 3 cases of HBV + HDV co-infection. Patients’ age ranged from 24 - 69 years with an average of 49.2 ± 12.2 years including 46.5 years for HBV and 51.9 years for HCV. The sex ratio was 1.56. The original transaminases were on average 93.37 IU/l for AST and 110.47 for ALT. The average RNA HCV was 1,685,331 IU/ml and the DNA HBV 33,312,767 IU/ml. Patients with HCV were of genotype 1 in 56.66%, genotype 2 in 40% and one case of genotype 4 (3.34%) from Central Africa. Fibrosis score at institution of treatment was significant (≥A2 and/or ≥F2) in 86.9% of cases of Fibrotest®, 100% of cases of Fibrometer®. We observed 48.8% of neutropenia